BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 27521318)

  • 1. Adult T-Cell Leukemia/Lymphoma: Rarely Encountered in the United States.
    Roe C; Komrokji R; Zhang L; Price S; Sokol L
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S191-4. PubMed ID: 27521318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete remission in two cases of adult T-cell leukemia/lymphoma treated with hyper-CVAD: a case report and review of the literature.
    Alduaij A; Butera JN; Treaba D; Castillo J
    Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):480-3. PubMed ID: 21156467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Features and Treatment Outcomes of 81 Patients with Aggressive Type Adult T-cell Leukemia-lymphoma at a Single Institution over a 7-year Period (2006-2012).
    Kawano N; Yoshida S; Kuriyama T; Tahara Y; Yamashita K; Nagahiro Y; Kawano J; Koketsu H; Toyofuku A; Manabe T; Beppu K; Ono N; Himeji D; Yokota-Ikeda N; Inoue S; Ochiai H; Sonoda KH; Shimoda K; Ishikawa F; Ueda A
    Intern Med; 2015; 54(12):1489-98. PubMed ID: 26073237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801.
    Tsukasaki K; Utsunomiya A; Fukuda H; Shibata T; Fukushima T; Takatsuka Y; Ikeda S; Masuda M; Nagoshi H; Ueda R; Tamura K; Sano M; Momita S; Yamaguchi K; Kawano F; Hanada S; Tobinai K; Shimoyama M; Hotta T; Tomonaga M;
    J Clin Oncol; 2007 Dec; 25(34):5458-64. PubMed ID: 17968021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of first-line chemotherapy on natural killer cells in adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
    Ogura M; Ishida T; Tsukasaki K; Takahashi T; Utsunomiya A
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):199-207. PubMed ID: 27289375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognosis of patients with adult T-cell leukemia/lymphoma in Japan: A nationwide hospital-based study.
    Imaizumi Y; Iwanaga M; Nosaka K; Ishitsuka K; Ishizawa K; Ito S; Amano M; Ishida T; Uike N; Utsunomiya A; Ohshima K; Tanaka J; Tokura Y; Tobinai K; Watanabe T; Uchimaru K; Tsukasaki K;
    Cancer Sci; 2020 Dec; 111(12):4567-4580. PubMed ID: 32976684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation.
    Gkotzamanidou M; Papadimitriou CA
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):248-61. PubMed ID: 24075060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study.
    Lefrère F; Delmer A; Suzan F; Levy V; Belanger C; Djabarri M; Arnulf B; Damaj G; Maillard N; Ribrag V; Janvier M; Sebban C; Casasnovas RO; Bouabdallah R; Dreyfus F; Verkarre V; Delabesse E; Valensi F; McIntyre E; Brousse N; Varet B; Hermine O
    Leukemia; 2002 Apr; 16(4):587-93. PubMed ID: 11960337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study on combination therapy with CHOP-Zenapax for HTLV-I associated adult T-cell leukaemia/lymphoma (ATLL).
    Ceesay MM; Matutes E; Taylor GP; Fields P; Cavenagh J; Simpson S; Ho A; Devereux S; Mufti GJ; Pagliuca A
    Leuk Res; 2012 Jul; 36(7):857-61. PubMed ID: 22209076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment outcome of elderly patients with aggressive adult T cell leukemia-lymphoma: Nagasaki University Hospital experience.
    Makiyama J; Imaizumi Y; Tsushima H; Taniguchi H; Moriwaki Y; Sawayama Y; Imanishi D; Taguchi J; Hata T; Tsukasaki K; Miyazaki Y
    Int J Hematol; 2014 Nov; 100(5):464-72. PubMed ID: 25209605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison of the efficiency of CHOP-based regimen with or without high dose consolidation treatment combined with hematopoietic stem cell transplantation in 63 lymphoblastic lymphoma patients].
    Qin Y; Shi YK; He XH; Han XH; Zhou SY; Liu P; Yang JL; Yang S; Zhang CG; Dong M; Zhou LQ; Wang JW; Feng FY; Sun Y
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):469-73. PubMed ID: 19950562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mogamulizumab Plus EPOCH Therapy for Patients With Newly Diagnosed Aggressive Adult T-cell Leukemia/lymphoma.
    Jo T; Matsuzaka K; Shioya H; Tominaga H; Sakai T; Kaneko Y; Hayashi S; Matsuo M; Taguchi J; Abe K; Shigematsu K; Kubota-Koketsu R
    Anticancer Res; 2020 Sep; 40(9):5237-5243. PubMed ID: 32878812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 90Y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward?
    Mondello P; Steiner N; Willenbacher W; Arrigo C; Cuzzocrea S; Pitini V; Mian M
    Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):82-8. PubMed ID: 26702476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of the Modified EPOCH Regimen (Etoposide, Vincristine, Doxorubicin, Carboplatin, and Prednisolone) for Adult T-cell Leukemia/Lymphoma: A Multicenter Retrospective Study.
    Tsukamoto Y; Kiyasu J; Choi I; Kozuru M; Uike N; Utsunomiya H; Hirata A; Fujioka E; Ohno H; Nakashima E; Nakashima Y; Miyashita K; Tachikawa Y; Narazaki T; Tsuda M; Haji S; Takamatsu A; Tanaka E; Goto T; Takatsuki H; Oyama M; Muta H; Yagi Y; Ikeda M; Matsushima T; Yufu Y; Suehiro Y
    Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e445-e453. PubMed ID: 32312633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adult T-cell leukemia-lymphoma.
    Tsukasaki K
    Hematology; 2012 Apr; 17 Suppl 1():S32-5. PubMed ID: 22507774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Data on Adult T-Cell Leukemia/Lymphoma in Latin America: A Study From the Grupo de Estudio Latinoamericano de Linfoproliferativos.
    Malpica L; Enriquez DJ; Castro DA; Peña C; Idrobo H; Fiad L; Prates M; Otero V; Biglione M; Altamirano M; Sandival-Ampuero G; Aviles-Perez U; Meza K; Aguirre-Martinez L; Cristaldo N; Maradei JL; Guanchiale L; Soto P; Viñuela JL; Cabrera ME; Paredes SR; Riva E; Di Stefano M; Noboa A; Choque JA; Candelaria M; Von Glasenapp A; Valvert F; Torres-Viera MA; Castillo JJ; Ramos JC; Villela L; Beltran BE
    JCO Glob Oncol; 2021 Jul; 7():1151-1166. PubMed ID: 34270330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology, clinical features, and outcome of HTLV-1-related ATLL in an area of prevalence in the United States.
    Malpica L; Pimentel A; Reis IM; Gotuzzo E; Lekakis L; Komanduri K; Harrington T; Barber GN; Ramos JC
    Blood Adv; 2018 Mar; 2(6):607-620. PubMed ID: 29545256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete remission and proviral load negativization after allogeneic-SCT in a patient with Adult T-cell lymphoma: Case report.
    Warley F; Cristaldo N; Barcan L; Valledor A; García-Rivello H; Arbelbide J; Basquiera AL; Otero V
    Transpl Infect Dis; 2020 Dec; 22(6):e13350. PubMed ID: 32500925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
    Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W
    J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.